HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

VX-659

a chloride channel corrector for the treatment of cystic fibrosis

Also Known As:

N-(phenylsulfonyl)-6-(3-(2-(1-(trifluoromethyl)cyclopropyl)ethoxy)-1H-pyrazol-1-yl)-2-(2,2,4-trimethyl-1-pyrrolidinyl)nicotinamide; VX659

Networked: 1 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Azoles: 2138
    - Pyrazoles: 61
      - VX-659: 1
  - Pyrrolidines: 115
    - VX-659: 1

Experts

1.	Brown, Cynthia: 1 article (10/2018)
2.	Davies, Jane C: 1 article (10/2018)
3.	Horsley, Alexander: 1 article (10/2018)
4.	Mall, Marcus A: 1 article (10/2018)
5.	McKee, Charlotte M: 1 article (10/2018)
6.	McKone, Edward F: 1 article (10/2018)
7.	Moskowitz, Samuel M: 1 article (10/2018)
8.	Plant, Barry J: 1 article (10/2018)
9.	Prais, Dario: 1 article (10/2018)
10.	Ramsey, Bonnie W: 1 article (10/2018)

Related Diseases

1.

Cystic Fibrosis (Mucoviscidosis)

10/25/2018 - "VX-659 triple-combination regimens have the potential to treat the underlying cause of disease in approximately 90% of patients with cystic fibrosis. "
10/25/2018 - "The next-generation cystic fibrosis transmembrane conductance regulator (CFTR) corrector VX-659, in triple combination with tezacaftor and ivacaftor (VX-659-tezacaftor-ivacaftor), was developed to restore the function of Phe508del CFTR protein in patients with cystic fibrosis. "

Related Drugs and Biologics

1.	Cystic Fibrosis Transmembrane Conductance Regulator (Protein, CFTR)
2.	ivacaftor drug combination tezacaftor